MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

REGENXBIO Inc

Ouvert

SecteurSoins de santé

9.08 3.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.74

Max

9.3

Chiffres clés

By Trading Economics

Revenu

8.4M

-51M

Ventes

-3M

21M

BPA

-1.01

Marge bénéficiaire

-241.284

Employés

353

EBITDA

17M

-38M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+253.26% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

37M

334M

Ouverture précédente

5.31

Clôture précédente

9.08

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

REGENXBIO Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 avr. 2025, 09:30 UTC

Actualités

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Comparaison

Variation de prix

REGENXBIO Inc prévision

Objectif de Prix

By TipRanks

253.26% hausse

Prévisions sur 12 Mois

Moyen 32.5 USD  253.26%

Haut 50 USD

Bas 12 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

7.82 / N/ASupport & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.